CNCR:NSD-Loncar Cancer Immunotherapy ETF (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 15.091

Change

-0.65 (-4.12)%

Market Cap

USD 0.01B

Volume

2.30K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The fund attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

Inception Date: 13/10/2015

Primary Benchmark: Loncar Cancer Immunotherapy TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.79%

Management Expense Ratio: 0.79 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
IBB iShares Biotechnology ETF 0.47 %

-0.56 (-0.39%)

USD 7.19B
PPH VanEck Pharmaceutical ETF 0.36 %

-0.05 (-0.06%)

USD 0.67B
BBH VanEck Biotech ETF 0.35 %

+0.36 (+0.21%)

USD 0.43B
PSCH Invesco S&P SmallCap Health Ca.. 0.29 %

-0.51 (-1.07%)

USD 0.18B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

-0.29 (-0.62%)

USD 0.14B
GNOM Global X Genomics & Biotechnol.. 0.00 %

+0.03 (+0.28%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

-0.07 (-0.23%)

USD 0.02B

ETFs Containing CNCR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.03% 88% B+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.03% 88% B+ 63% D
Trailing 12 Months  
Capital Gain 45.67% 88% B+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.67% 88% B+ 79% B-
Trailing 5 Years  
Capital Gain -28.10% 13% F 33% F
Dividend Return 10.20% 86% B+ 34% F
Total Return -17.90% 25% F 34% F
Average Annual (5 Year Horizon)  
Capital Gain -6.41% 13% F 25% F
Dividend Return -4.59% 13% F 27% F
Total Return 1.82% 100% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 31.54% 38% F 59% D-
Risk Adjusted Return -14.56% 13% F 27% F
Market Capitalization 0.01B 13% F 15% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.